Lonza Group AG (LONN.SW)
- Previous Close
513.80 - Open
518.60 - Bid 522.20 x --
- Ask 522.40 x --
- Day's Range
516.60 - 522.60 - 52 Week Range
308.60 - 599.40 - Volume
28,360 - Avg. Volume
220,196 - Market Cap (intraday)
37.674B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
58.76 - EPS (TTM)
8.89 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 4.00 (0.78%)
- Ex-Dividend Date May 13, 2024
- 1y Target Est
715.25
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
www.lonza.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LONN.SW
Performance Overview: LONN.SW
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LONN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LONN.SW
Valuation Measures
Market Cap
37.05B
Enterprise Value
38.52B
Trailing P/E
57.86
Forward P/E
40.82
PEG Ratio (5yr expected)
4.10
Price/Sales (ttm)
5.64
Price/Book (mrq)
3.92
Enterprise Value/Revenue
5.73
Enterprise Value/EBITDA
25.61
Financial Highlights
Profitability and Income Statement
Profit Margin
9.74%
Return on Assets (ttm)
5.00%
Return on Equity (ttm)
6.49%
Revenue (ttm)
6.72B
Net Income Avi to Common (ttm)
654M
Diluted EPS (ttm)
8.89
Balance Sheet and Cash Flow
Total Cash (mrq)
1.67B
Total Debt/Equity (mrq)
32.93%
Levered Free Cash Flow (ttm)
215.12M
Research Analysis: LONN.SW
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: LONN.SW
LONN.SW does not have Company Insights